种族不平等在阿片类药物使用障碍的药物治疗中:探索使用的潜在促进因素和障碍。
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
机构信息
Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, United States.
University of Pittsburgh School of Medicine, Division of General Internal Medicine, United States; University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, United States.
出版信息
Drug Alcohol Depend. 2021 Oct 1;227:108927. doi: 10.1016/j.drugalcdep.2021.108927. Epub 2021 Jul 28.
BACKGROUND
Despite evidence that individuals with opioid use disorder (OUD) have a lower risk of mortality when using evidence-based medications for OUD (MOUD), only 20 % of people with OUD receive MOUD. Black patients are significantly less likely than White patients to initiate MOUD. We measured the association between various facilitators and barriers to initiation, including criminal justice, human services, and health care factors, and variation in initiation of MOUD by race.
METHODS
We used data from a comprehensive, linked data set of health care, human services, and criminal justice programs from Allegheny County in Western Pennsylvania to measure disparities in MOUD initiation by race in the first 180 days after an OUD diagnosis, as well as mediation by potential facilitators and barriers to treatment, among Medicaid enrollees. This is a cross-sectional analysis.
RESULTS
Among 6374 Medicaid enrollees who met study criteria, Black enrollees were 18.2 percentage points less likely than White enrollees to start MOUD after controlling for gender, age, and Medicaid eligibility (95 % CI: -21.5 % - -14.8 %). Each day in the emergency department or county jail was associated with a decrease in the likelihood of initiation, as was the presence of a non-OUD substance use disorder diagnosis or participation in intensive non-MOUD treatment. Mediators accounted for approximately one-fifth of the variation in initiation related to race.
CONCLUSIONS
Acute care facilities and settings in which people with OUD are incarcerated may have an opportunity to increase the use of MOUD overall and close the racial gap in initiation.
背景
尽管有证据表明,患有阿片类药物使用障碍(OUD)的个体在使用基于证据的 OUD 治疗药物(MOUD)时死亡风险较低,但只有 20%的 OUD 患者接受 MOUD 治疗。黑人患者接受 MOUD 治疗的可能性明显低于白人患者。我们衡量了启动 MOUD 的各种促进因素和障碍(包括刑事司法、社会服务和医疗保健因素)与种族之间 MOUD 启动率差异之间的关联。
方法
我们使用了来自宾夕法尼亚州西部阿勒格尼县综合的、与医疗保健、社会服务和刑事司法项目相关联的数据,来衡量在 OUD 诊断后的头 180 天内,按种族划分的 MOUD 启动率差异,以及在医疗补助计划参与者中,潜在的治疗促进因素和障碍的调解作用。这是一项横断面分析。
结果
在符合研究标准的 6374 名医疗补助计划参与者中,黑人参与者在控制了性别、年龄和医疗补助资格后,开始 MOUD 的可能性比白人参与者低 18.2 个百分点(95%置信区间:-21.5%至-14.8%)。每天在急诊室或县监狱都会降低启动的可能性,非 OUD 物质使用障碍诊断或参加强化非 MOUD 治疗也是如此。调解因素大约解释了与种族相关的启动率差异的五分之一。
结论
急性护理机构和监禁 OUD 患者的场所可能有机会增加 MOUD 的总体使用,并缩小启动率方面的种族差距。